Form 6-K GENETIC TECHNOLOGIES For: May 04
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated May 4, 2015
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 4, 2015 |
| ||
|
| ||
|
GENETIC TECHNOLOGIES LIMITED | ||
|
| ||
|
| ||
|
By: |
/s/ Bronwyn Christie | |
|
|
Name: |
Bronwyn Christie |
|
|
Title: |
Company Secretary |
Exhibit 99.1
ASX ANNOUNCEMENT
4 May 2015
Second of Two Nasdaq Deficiencies Successfully Remediated
Melbourne, Australia, 4 May 2015: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company) is pleased to report that the second of two Nasdaq deficiencies, previously notified to the market, has been successfully remediated.
On 6 November 2014, the Company announced that it had received a letter dated 5 November 2014, from the Nasdaq Stock Market notifying the Company that, companies listed on the Nasdaq Capital market are required to maintain a minimum of USD 2.5 million in stockholder equity for continued listing. Since the Companys Form 20-F, for the fiscal year ended June 30 2014, reported stockholders equity of approximately USD 1.7 million, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complied with the Nasdaq Marketplace Listing Rules (the Rules).
The letter stated that in accordance with the Rules the Company had 45 calendar days, or until 22 December 2014, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant the Company an extension of up to 180 calendar days from November 5, 2014 to evidence compliance.
On 28 January 2015, the Company received a letter from Nasdaq, dated 27 January 2015, advising that it had been granted an extension of time (on or before May 4, 2015) to regain compliance with the minimum stockholders equity requirement.
The Company is of the view that it has now regained compliance with the stockholders equity requirement based upon the following transactions that have been reported to the Market since September 2014, as follows:
· during September 2014, the Company finalised the raising of $2,150,000, via the issue of unlisted secured (debt) notes;
· on 19 November 2014, the Company announced that it had completed the sale of the Companys heritage Australian genetics business for $2,000,000, in cash;
· on 30 December 2014, the Company advised of the issue of new shares, via the Share Purchase Plan (SPP) raising $257,500, before associated costs;
· the receipt of $1,844,500 since 30 January 2015, from the exercise of options to purchase more shares in the Company, which were attached to the unlisted secure debt note issued;
· as at the date of this announcement, the Company has received $2,603,111, before associated costs, via the issue of equity as part of the standby Equity Placement Facility Agreement, with the Kentgrove Capital Growth Fund, an investment fund managed by Kentgrove Capital Pty Ltd; and
· on 6 March 2015, the Company announced the raising of approximately $18.6 million, before associated costs, from professional and sophisticated investors in the United States.
Genetic Technologies Limited · Website: www.gtglabs.com · Email: [email protected] ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia
Phone +61 3 8412 7000 · Fax +61 3 8412 7040
On 27 April 2015, the Company announced, as part of its Appendix 4C of the ASX Listing Rules, that it had cash on hand, as at 31 March 2015, of $20,176,450.
As at 31 March 2015, the net assets position of the Company stood at $21 million (approximately USD 16 million), which satisfies the Nasdaq stockholders equity requirement for continued listing.
Note that these rules only apply to the Companys common stock trading on the Nasdaq Capital Market and not the Companys share trading on the Australian Securities Exchange, the Companys home exchange.
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli |
|
Candice Knoll (USA) |
Chief Executive Officer |
|
Blueprint Life Science Group |
Genetic Technologies Limited |
|
+1 (415) 375 3340, Ext. 105 |
+ 61 3 8412 7050 |
|
|
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage womens health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus® improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus® expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus®, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus® to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Sachem Capital Sets Dates for 2023 Earnings Release and Conference Call
- Inovalis Real Estate Investment Trust Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2023
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!